Endocrine cells in the ileum of patients with irritable bowel syndrome by El-Salhy, Magdy et al.
Endocrine cells in the ileum of patients with irritable bowel 
syndrome
Magdy El-Salhy, Odd Helge Gilja, Doris Gundersen, Jan Gunnar Hatlebakk, Trygve Hausken
Magdy El-Salhy, Section for Gastroenterology, Department of 
Medicine, Stord Helse-Fonna Hospital, 54 09 Stord, Norway
Doris Gundersen, Department of Research, Helse-Fonna, 55 01 
Haugesund, Norway
Magdy El-Salhy, Odd Helge Gilja, Jan Gunnar Hatlebakk, 
Trygve Hausken, Section for Gastroenterology, Department of 
Clinical Medicine, University of Bergen, 50 00 Bergen, Norway
Author contributions: El-Salhy M designed the study, per-
formed research, analyzed the results, and wrote the manuscript; 
Gilja OH, Gundersen D, Hatlebakk JG and Hausken T con-
tributed equally to the study design, analysis of the results, and 
commenting upon the manuscript; All the authors approved the 
submitted version of the manuscript.
Supported by A Grant from Helse-Fonna
Correspondence to: Magdy El-Salhy, Professor, Consultant 
Gastroenterologist, Section for Gastroenterology, Department 
of Medicine, Stord Helse-Fonna Hospital, Box 4000, 54 09 Stord, 
Norway. magdy.el-salhy@helse-fonna.no
Telephone: +47-53-491000       Fax: +47-53-491001
Received: September 10, 2013  Revised: October 20, 2013
Accepted: November 18, 2013
Published online: March 7, 2014
Abstract
AIM: To study the ileal endocrine cell types in irritable 
bowel syndrome (IBS) patients.
METHODS: Ninety-eight patients with IBS (77 females 
and 21 males; mean age 35 years, range 18-66 years) 
were included, of which 35 patients had diarrhea 
(IBS-D), 31 patients had a mixture of both diarrhea 
and constipation (IBS-M), and 32 patients had con-
stipation (IBS-C) as the predominant symptoms. The 
controls were 38 subjects (26 females and 12 males; 
mean age 40 years, range 18-65 years) who had 
submitted to colonoscopy for the following reasons: 
gastrointestinal bleeding, where the source of bleeding 
was identified as hemorrhoids (n  = 24) or angiodyspla-
sia (n  = 3), and health worries resulting from a relative 
being diagnosed with colon carcinoma (n  = 11). The 
patients were asked to complete the: Birmingham IBS 
symptom questionnaire. Ileal biopsy specimens from 
all subjects were immunostained using the avidin-
biotin-complex method for serotonin, peptide YY (PYY), 
pancreatic polypeptide (PP), enteroglucagon, and so-
matostatin cells. The cell densities were quantified by 
computerized image analysis, using Olympus cellSens 
imaging software.
RESULTS: The gender and age distributions did not 
differ significantly between the patients and the con-
trols (P  = 0.27 and P  = 0.18, respectively). The total 
score of Birmingham IBS symptom questionnaire was 
21 ± 0.8, and the three underlying dimensions: pain, 
diarrhea, and constipation were 7.2 ± 0.4, 6.6 ± 0.4, 
and 7.2 ± 0.4, respectively. The density of serotonin 
cells in the ileum was 40.6 ± 3.6 cells/mm2 in the 
controls, and 11.5 ± 1.2, 10.7 ± 5.6, 10.0 ± 1.9, and 
13.9 ± 1.4 cells/mm2 in the all IBS patients (IBS-total), 
IBS-D, IBS-M, and IBS-C patients, respectively. The 
density in the controls differed significantly from those 
in the IBS-total, IBS-D, IBS-M, and IBS-C groups (P  < 
0.0001, P  = 0.0001, P  = 0.0001, and P  < 0.0001, re-
spectively). There was a significant inverse correlation 
between the serotonin cell density and the pain dimen-
sion of Birmingham IBS symptom questionnaire (r  = 
-0.6, P  = 0.0002). The density of PYY cells was 26.7 ± 
1.6 cells/mm2 in the controls, and 33.1 ± 1.4, 27.5 ± 
1.4, 34.1 ± 2.5, and 41.7 ± 3.1 cells/mm2 in the IBS-
total, IBS-D, IBS-M, and IBS-C patients, respectively. 
This density differed significantly between patients with 
IBS-total and IBS-C and the controls (P  = 0.03 and < 
0.0001, respectively), but not between controls and, 
IBS-D, and IBS-M patients (P  = 0.8, and P  = 0.1, re-
spectively). The density of PYY cells correlated signifi-
cantly with the degree of constipation as recorded by 
the Birmingham IBS symptom questionnaire (r  = 0.6, 
P  = 0.0002). There were few PP-, enteroglucagon-, 
and somatostatin-immunoreactive cells in the biopsy 
material examined, which made it impossible to reliably 
quantify these cells.
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CONCLUSION: The decrease of ileal serotonin cells 
is associated with the visceral hypersensitivity seen in 
all IBS subtypes. The increased density of PYY cells in 
IBS-C might contribute to the constipation experienced 
by these patients.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The present study investigated for the first 
time the ileal endocrine cells in patients with irritable 
bowel syndrome (IBS). It included a relatively a large 
cohort of patients and comprising all the IBS subtypes, 
namely diarrhea (IBS-D), a mixture of both diarrhea 
and constipation (IBS-M) and constipation (IBS-C). It 
showed that the density of serotonin cells is reduced 
in patients with IBS, regardless of the subtype. On the 
other hand the density of peptide YY (PYY) cells in the 
ileum of IBS-D and IBS-M patients did not differ from 
that of controls, but was significantly elevated in those 
with IBS-C. It was concluded that the reduction of ileal 
serotonin cells may be connected to the visceral hyper-
sensitivity seen in all IBS subtypes and that increase in 
the PYY cell density in IBS-C, would slow the intestinal 
transit and cause constipation.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a common chronic 
gastrointestinal functional disorder that is characterized 
by abdominal discomfort or pain, altered bowel habits, 
and bloating/abdominal distension[1,2]. IBS reportedly has 
a prevalence of  5%-20% and an incidence of  about 200 
per 100000 of  the adult population[2-9]. IBS reduces the 
quality of  life considerably in IBS patients and is an eco-
nomic burden to society for various reasons, including 
overconsumption of  healthcare resources and increased 
sick leave[10]. However, IBS is not known to be associ-
ated with the development of  serious disease or with 
increased mortality[11,12].
The diagnosis of  IBS is based on the assessment of  
symptoms and detailed, accurate, and clinically useful 
definitions of  the syndrome that have been elaborated by 
the working parties responsible for producing the latest 
Rome Ⅲ Criteria[13,14]. In addition to these criteria, warn-
ing symptoms (so-called red flags) such as age > 50 years, 
short history of  symptoms, nocturnal symptoms, weight 
loss, rectal bleeding, anemia, and the presence of  markers 
for inflammation or infections should be excluded. IBS 
patients are sub-grouped on the basis of  differences in 
the predominant bowel symptoms into diarrhea (IBS-D), 
constipation (IBS-C), both diarrhea and constipation 
(IBS-M), and un-subtyped IBS in patients with insuffi-
cient abnormality of  stool consistency to meet criteria for 
IBS-C, -D, or -M[13,14]. Because of  the overlap of  sympto-
mology with celiac disease and microscopic colitis, some 
gastroenterologists (including the present authors) believe 
that these disorders should be excluded in addition to ap-
plying the Rome Criteria[15].
Abnormalities in the endocrine cells in the stomach, 
duodenum, colon, and rectum have been reported in 
patients with IBS[16-29], but the ileal endocrine cells have 
not been investigated previously. The endocrine cell types 
differ markedly between the distal and proximal small 
intestine, probably due to the quite different functions 
performed by these two parts of  the intestine. The proxi-
mal small intestine contains serotonin, secretin, cholecys-
tokinin (CCK), gastric inhibitory polypeptide (GIP), and 
somatostatin cells, while the ileum has the same endo-
crine cell types as in the large intestine, namely serotonin, 
peptide YY (PYY), pancreatic polypeptide (PP), entero-
glucagon, and somatostatin cells[30].
A recent study observed endocrine cell depletion in 
the ileum of  patients with sporadic IBS[31]. This depletion 
was detected by chromogranin A, which is a common 
marker for endocrine cells[32-34]. The aim of  the present 
study was to clarify the affected endocrine cell types by 
examining various ileal endocrine cells in the same cohort 
of  IBS patients investigated using chromogranin A.
MATERIALS AND METHODS
Patients and controls
Ninety-eight patients (77 females and 21 males; mean 
age 35 years, range 18-66 years) with IBS according to 
Rome Ⅲ Criteria were included in the study[13,14]. The 
IBS subtypes were distributed as follows: 35 patients 
with IBS-D, 31 patients with IBS-M, and 32 patients with 
IBS-C. Symptoms had been present in all of  the patients 
for many years, and the onset of  their IBS symptoms 
could not be associated with any events, in particular gas-
trointestinal or other infections. All patients underwent 
a complete physical examination and were investigated 
using the following blood tests: full blood count, elec-
trolytes, inflammatory markers, liver tests, and thyroid 
function tests. They also underwent further gastroscopy 
with duodenal biopsies, which were used to exclude celiac 
disease. All of  the patients had been tested previously (i.e., 
before they were referred to us) for lactose intolerance 
and the presence of  intestinal infectious agents including 
parasites in the stool; the results of  all of  these tests were 
negative.
For comparison, the control group comprised 38 
subjects (26 females and 12 males; mean age 40 years, 
range 18-65 years) who had submitted to colonoscopy 
for the following reasons: gastrointestinal bleeding, 
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where the source of  bleeding was identified as hemor-
rhoids (n = 24) or angiodysplasia (n = 3), and health 
worries resulting from a relative being diagnosed with 
colon carcinoma (n = 11).
The patients were asked to complete the: Birming-
ham IBS symptom questionnaire. The Birmingham IBS 
symptom score questionnaire is a disease specific score to 
measure the symptoms of  patients with IBS. It has been 
developed to be suitable for self-completion and has 
been found to be acceptable to patients. Its dimensions 
have good reliability, external validity and sensitivity[35]. 
The questionnaire comprises 11 questions based on the 
frequency of  IBS related symptoms. Each question has 
a standard response scale with symptoms all being mea-
sured on a 5-point Likert scale ranging from 0 ("none of  
the time") to 5 ("all of  the time"). There are three under-
lying dimensions: pain (3 items), diarrhea (5 items) and 
constipation (3 items)[35].
The study was performed in accordance with the 
Declaration of  Helsinki and was approved by the Region-
al Committee for Medical and Health Research Ethics 
West, Bergen, Norway. All subjects gave oral and written 
consent to participate.
Colonoscopy, histopathology, and 
immunohistochemistry
Colonoscopy was performed on both the patients and 
the controls, segmental biopsy specimens were taken 
from the colon and rectum, and four biopsy samples 
were taken from the ileum of  each subject. The biopsy 
samples were fixed overnight in 4% buffered parafor-
maldehyde, embedded in paraffin, and cut into 5-m sec-
tions. The sections were stained with hematoxylin-eosin, 
and immunostained by the avidin-biotin complex (ABC) 
method using the Vectastain ABC kit (Vector Laborato-
ries). The sections were hydrated and immersed in 0.01% 
hydrogen peroxide in PBS buffer (pH 7.4) for 10 min to 
inhibit endogenous peroxidase. After washing in buffer, 
the sections were treated with 1% bovine serum albumin 
for 30 min to block the nonspecific binding sites, and 
then incubated with the primary antiserum/antibody 
at room temperature for 2 h. The sections were then 
washed in PBS buffer and incubated with biotinylated 
swine anti-mouse (in the case of  monoclonal antibodies) 
or anti-rabbit IgG (in the case of  polyclonal antibod-
ies) diluted 1:200 for 30 min at room temperature. After 
washing the slides in PBS buffer, the sections were incu-
bated for 30 min with avidin-biotin-peroxidase complex 
diluted 1:100, and then immersed in 3,3’-diaminobenzi-
dine (DAB) peroxidase substrate (Vector laboratories), 
followed by counterstaining in hematoxylin[18]. The 
following primary antisera/antibodies were used: mono-
clonal mouse anti-serotonin (Dako, code no. 5HT-209), 
polyclonal anti-porcine peptide PYY (Alpha-Dagnostica, 
code PYY 11A), polyclonal rabbit anti-synthetic-human 
PP (Diagnostic Biosystems, code No. 114), polyclonal 
rabbit anti-porcine glicentin/glucagon (Acris Antibodies, 
code BP508), and polyclonal rabbit anti-synthetic-human 
somatostatin (Dako, code no. A566); these antibodies 
were used at dilutions of  1:1500, 1:1000, 1:800, 1:400, 
and 1:200, respectively.
Computerized image analysis
Quantification of  the endocrine cells was done as de-
scribed previously[36,37]. Measurements were performed 
using Olympus cellSens imaging software (version 1.7) 
on a computer linked to an Olympus microscope type 
BX 43 with an Olympus camera (DP 26). The number 
of  immunoreactive cells and the area of  the epithelial 
cells were measured. The numbers of  endocrine cells in 
each field were counted manually by pointing and click-
ing the computer mouse, and the areas of  the epithelium 
containing these cells were drawn manually using the 
computer mouse. A × 40 objective was used, for which 
each frame (field) on the monitor represented a tissue 
area of  0.14 mm2. Each individual and peptide hormone 
was measured in ten randomly chosen fields. Immunos-
tained sections from the IBS patients and controls were 
coded and mixed, and measurements were made by the 
same person (El-Salhy M) who was blind to the identity 
of  the sections. The data from the fields were tabulated, 
and the cell density of  the epithelium (in cells/mm2) was 
computed and statistically analyzed.
Statistical analysis
The gender difference between patients and controls was 
tested by Fisher’s exact test, and the age difference was 
tested by the Mann-Whitney nonparametric test. Dif-
ferences between controls, all IBS patients (IBS-total), 
IBS-D, IBS-M, and IBS-C patients were tested by the 
Kruskal-Wallis nonparametric test with Dunn’s post-test. 
Correlation was done by Spearman nonparametric test. 
The data are presented as mean ± SE values, and differ-
ences with P < 0.05 were considered to be statistically 
significant.
RESULTS
Gender and age characteristics of patients and controls
The gender and age distributions did not differ signifi-
cantly between the patients and the controls (P = 0.27 
and P = 0.18, respectively). The total score of  Birming-
ham IBS symptom questionnaire was 21 ± 0.8, and the 
three underlying dimensions: pain, diarrhea, and constipa-
tion were 7.2 ± 0.4, 6.6 ± 0.4, and 7.2 ± 0.4, respectively.
Endoscopy, histopathology, and immunohistochemistry
The colon and rectum of  both the patients and the con-
trol subjects were macroscopically normal. The ileum 
was macroscopically normal in all except in one control 
subject and three patients, in whom lymphoid hyperpla-
sia was observed; this condition is a common finding in 
young individuals and has no pathological relevance. The 
results of  histopathological examinations of  the ileum, 
colon, and rectum were normal in both the patients and 
the controls.
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PP, enteroglucagon, and somatostatin cell densities: 
There were few PP-, enteroglucagon-, and somatostatin-
immunoreactive cells in the biopsy material examined, 
which made it impossible to reliably quantify these cells.
DISCUSSION
The present study showed that the density of  serotonin 
cells in the ileum is reduced in patients with sporadic 
(nonspecific) IBS, regardless of  the subtype. This finding 
is similar to that reported in the colon of  IBS patients[19]. 
On the other hand the density of  PYY cells in the ileum 
of  IBS-D and IBS-M patients did not differ from that 
of  controls, but was significantly elevated in those with 
IBS-C. The observations made here on PYY cell density 
differ from those reported in the colon, where the den-
sity of  PYY cells was reduced in IBS patients.
Abnormalities in the endocrine cells in the stomach, 
duodenum, colon, and rectum have been reported in 
patients with IBS[16-29]. The density of  ghrelin cells in the 
stomach is lower in IBS-C and higher in IBS-D than in 
healthy controls[16]. In the duodenum, the cell densities of  
GIP and somatostatin are decreased in both IBS-D and 
IBS-C[18]. The densities of  duodenal secretin and CCK 
cells are decreased in IBS-D but unchanged in IBS-C[18]. 
The duodenal serotonin cells are not affected in both 
IBS-D and IBS-C[18]. Postinfectious IBS was found to 
be associated with increased numbers of  duodenal CCK 
cells but decreased numbers of  serotonin cells[17]. Co-
lonic serotonin and PYY cell densities have been found 
Serotonin-, PYY-, PP-, enteroglucagon-, and soma-
tostatin-immunoreactive cells were found in the ileum of  
all of  the subjects (i.e., patients and controls), mostly in 
the crypts. These cells were basket- or flask-shaped.
Computerized image analysis
Serotonin cell density: The density of  serotonin cells in 
the ileum was 40.6 ± 3.6 cells/mm2 in the controls, and 
11.5 ± 1.2, 10.7 ± 5.6, 10.0 ± 1.9, and 13.9 ± 1.4 cells/mm2 
in the IBS-total, IBS-D, IBS-M, and IBS-C patients, re-
spectively. The serotonin cell density differed significantly 
between the controls and the IBS-total and IBS subgroups 
(P < 0.0001). Posttests showed that the density in the 
controls differed significantly from those in the IBS-total, 
IBS-D, IBS-M, and IBS-C groups (P < 0.0001, P = 0.0001, 
P = 0.0001, and P < 0.0001, respectively) (Figures 1 and 
2). There was a significant inverse (negative) correlation 
between the serotonin cell density and the pain dimension 
of  Birmingham IBS symptom questionnaire (r = -0.6, P = 
0.0002). There was no significant correlation between the 
total score of  Birmingham IBS symptom questionnaire, the 
diarrhea or constipation dimension (r = -0.05, P = 0.8; r = 
-0.4, P = 0.8; and r = -0.2, P = 0.2 respectively). The density 
of  PYY cells was 26.7 ± 1.6 cells/mm2 in the controls, and 
33.1 ± 1.4, 27.5 ± 1.4, 34.1 ± 2.5, and 41.7 ± 3.1 cells/mm2 
in the IBS-total, IBS-D, IBS-M, and IBS-C patients, respec-
tively. The PYY cell density differed significantly between 
the controls and the IBS-total and IBS subgroups (P < 
0.0001). This density differed significantly between patients 
with IBS-total and IBS-C and the controls (P = 0.03 and < 
0.0001, respectively), but not between controls and, IBS-D, 
and IBS-M patients (P = 0.8, and P = 0.1, respectively) 
(Figures 3 and 4). The density of  PYY cells correlated sig-
nificantly with the degree of  constipation as recorded by 
the Birmingham IBS symptom questionnaire (r = 0.6, P = 
0.0002). There was not significant correlation between the 
cell density of  PYY and the total Birmingham IBS symp-
tom questionnaire, the pain-, or diarrhea dimension (r = 0.2, 
P = 0.2; r = 0.2, P = 0.06; and r = 0.1, P = 0.5 respectively).
N
um
be
r 
of
 c
el
ls
/m
m
2  
ep
ith
el
iu
m
 
(m
ea
n 
±
 S
E)
Serotonin cell density
Controls     IBS-total     IBS-D      IBS-M       IBS-C 
100
80
60
40
20
0
Figure 1   Serotonin cell densities in the ileum of controls and in all pa-
tients with irritable bowel syndrome, patients with diarrhea as the predomi-
nant symptom, patients with both diarrhea and constipation, and patients 
with constipation as the predominant symptom patients. bP < 0.01 vs con-
trols. IBS-total: All patients with irritable bowel syndrome; IBS-D: Patients with 
diarrhea as the predominant symptom; IBS-M: Patients with both diarrhea and 
constipation; IBS-C: Patients with constipation as the predominant symptom.
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Figure 2  Ileal serotonin-immunoreactive cells in a control subject (A) and 
a patient with irritable bowel syndrome (B).
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to be low in both IBS-D and IBS-C[19]. In the rectum of  
patients with sporadic (nonspecific) IBS, the densities of  
PYY and enteroglucagon cells were significantly lower 
and that of  somatostatin cells was significantly higher in 
both IBS-D and IBS-C than in the controls, whereas the 
serotonin cell density in these patients did not differ from 
that in healthy controls[21,38]. Rectal serotonin and PYY 
cell densities in postinfectious IBS have been reported to 
be elevated[23,25,27,39,40].
Serotonin cells are the predominant endocrine cell 
type in the ileum, which could account for the general 
reduction of  ileal endocrine cells reported elsewhere[31]. 
Each intestinal crypt contains four to six pluripotent stem 
cells that differentiate through a series of  cellular precur-
sors (progenitors) into all epithelial cell types including 
enterocytes, goblet cells, Paneth cells, and endocrine 
cells[41-57]. It is possible that the reduction in ileal serotonin 
cells in IBS patients is due to abnormal cell differentia-
tion from stem cell. This assumption gets support from 
the findings that depletions of  endocrine cell in rejected 
ileum transplants are associated with marked depression 
in the expression of  neurogenin-3 (NEUROG3) which is 
a early progenitor for endocrine cells and NeuroD, which 
is a transcription factor expressed by cells derived from 
NEUROG3[58]. Furthermore, a mutant NEUROG3 has 
been described in patients with congenital malabsorption 
diarrhea and lack of  intestinal endocrine cells[59].
Serotonin activates the submucosal sensory branch 
of  the enteric nervous system that conveys sensation 
from the gut to the central nervous system[60,61]. Serotonin 
modulates is known to modulate visceral sensitivity of  
the gastrointestinal tract[62,63]. It is therefore conceivable 
to conclude that the reduction of  ileal serotonin cells may 
be connected to the visceral hypersensitivity seen in all 
IBS subtypes. It is difficult to establish whether the reduc-
tion in these ileal serotonin cells is primary or secondary 
to the visceral hypersensitivity. However, it is tempting to 
speculate that this abnormality is secondary to the visceral 
hypersensitivity and represents an adaptation mechanism 
for reducing the sensation conveyed from the gut to the 
central nervous system by serotonin. This assumption 
gets support from the present finding that serotonin cell 
density is correlated inversely to the pain score obtained 
by the Birmingham IBS symptom questionnaire. Speaking 
against this assumption are the findings that tryptophan 
hydroxylase (TPH)-1, which is the limiting enzyme for 
the synthesis in serotonin cells, and serotonin transporter 
(SERT) mRNA levels have been reported to be lower in 
the rectum and sigmoid colon of  IBS patients than con-
trol subjects[64]. There was no difference, however, in the 
levels of  (TPH)-1 and SERT between IBS patients with 
rectal hypersensitivity and those without[64].
PYY stimulates the absorption of  water and electro-
lytes, and is a major regulator of  the “ileal brake”[65-70]. 
Furthermore, PYY inhibits prostaglandin E2 and vaso-
active intestinal polypeptide (VIP), which stimulate intes-
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Figure 3  Peptide YY cell densities in the ileum of controls and in all 
patients with irritable bowel syndrome, patients with diarrhea as the 
predominant symptom, patients with both diarrhea and constipation, and 
patients with constipation as the predominant symptom patients. aP < 
0.05, bP < 0.01 vs controls. PYY: Peptide YY;  IBS-total: All patients with irritable 
bowel syndrome; IBS-D: Patients with diarrhea as the predominant symptom; 
IBS-M: Patients with both diarrhea and constipation; IBS-C: Patients with consti-
pation as the predominant symptom.
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Figure 4  Peptide YY cells in the ileum of a control subject (A), a patient 
with irritable bowel syndrome into diarrhea (B), and a patient with irritable 
bowel syndrome into constipation (C).
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tinal fluid secretion[71-73]. Administration of  PYY inhibits 
diarrhea in experimental mouse models by reducing 
intestinal fluid secretion and slowing colonic transit[74]. It 
is thus possible that the increase in the PYY cell density 
in IBS-C patients, and consequently the increase in PYY, 
would slow the intestinal transit by strengthening the ile-
al brake, increasing the absorption of  water, and decreas-
ing the secretion of  the intestinal fluid in the distal small 
intestine via inhibiting VIP and prostaglandin E2. These 
effects would in turn cause constipation. In support of  
this conclusion is the observation that the density PYY 
cell correlated to the constipation score calculated from 
the Birmingham IBS symptom questionnaire.
The above summary indicates that most of  the re-
ported abnormalities in gastrointestinal endocrine cells 
are similar in all IBS subtypes[18,20,28-31]. However, in IBS-C 
the density of  ghrelin cells in the oxyntic mucosa of  
the stomach was significantly lower than in healthy con-
trols[16]. In addition to its role in regulating appetite and 
energy metabolism, ghrelin accelerates gastric and small- 
and large-intestinal motility[75-88]. It can be speculated 
that the low density of  ghrelin cells previously reported 
and the high density of  PYY cells observed in the pres-
ent study explain why constipation predominates in the 
IBS-C subtype. On the other hand, in IBS-D patients the 
density of  ghrelin cells in the stomach was significantly 
higher and the densities of  duodenal secretin and CCK 
were lower than healthy volunteers[16,18]. Secretin inhibits 
gastric emptying and intestinal motility, and stimulates 
pancreatic bicarbonate and fluid secretions[30,89,90]. The 
secretion of  pancreatic bicarbonate increases the pH of  
gut contents, which are highly acidic after leaving the 
stomach, and this is essential for lipid digestion as pan-
creatic lipase is irreversibly inactivated below pH 4.0[91]. 
CCK relaxes the proximal stomach in order to increase 
its reservoir capacity, inhibits gastric emptying and stimu-
lates gall bladder contractions and pancreatic exocrine 
secretions of  digestive enzymes from pancreatic exocrine 
glands[91-94]. The low densities of  secretin and CCK cells 
in IBS-diarrhea patients could cause a rapid gastric emp-
tying and acceleration of  intestinal motility and ultimately 
diarrhea in these patients.
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peptide Y (PYY) cells in the ileum of patients with IBS-D and IBS-, did not differ 
from that of controls, but was significantly elevated in IBS-C. It was concluded 
that the reduction of ileal serotonin cells may play a role in visceral hypersensi-
tivity seen in IBS and that increase in the PYY cell density in IBS-C, may affect 
the intestinal transit and cause constipation.
Innovations and breakthroughs
The present study showed that the endocrine cells of the ileum of patients 
with IBS are abnormal. This together with the previously published results in 
the duodenum as well as in the stomach and large intestine of these patients 
indicate that the endocrine cells in all the segments of the gastrointestinal tract 
are affected. The gastrointestinal endocrine cells have specialized microvilli 
that project into the lumen and function as sensors for the luminal content and 
respond to luminal stimuli by releasing hormones into the lamina propria, which 
starts a chain reactions that progress throughout the entire neuroendocrine 
system. It is possible, therefore, that abnormalities the gut endocrine cells play 
a central role in the pathogenesis of IBS.
Applications
Identifying abnormalities in the gut endocrine cells may provide an effective tool 
in the treatment of IBS. Actually, a serotonin agonist is available in the market, 
which is approved for the treatment of chronic constipation.
Peer review
The study addresses the interesting areas of endocrine cells in IBS. The au-
thors present a well conducted and written histologic study of enteroendocrine 
cell types in the ileum of IBS patients, correlating cell densities with symptoms 
and comparing them to control subjects.
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